Abstract
Objective
IgG4-related disease (IgG4-RD) can involve many organs, including thyroid and orbital tissues. A link between IgG4, Graves’ disease (GD) and Graves’ orbitopathy (GO) has been proposed, but results are conflicting. Here we investigated the possible association between IgG4 and GO.
Methods
Retrospective investigation in 297 patients with Graves’ disease (GD), 152 with GO. Primary outcome: prevalence of IgG4 ≥ 135 mg/dL (cut-off for IgG4-RD). Secondary objectives: (1) serum IgG4 concentrations; (2) IgG4/IgG ratio; (3) prevalence of IgG4/IgG ratio ≥ 8.0%; (4) relationship between IgG4 and eye features; (5) relationship between IgG4 and anti-TSH receptor antibodies (TRAbs).
Results
Because GO patients had lower FT3 concentrations, we evaluated the main objectives in the second and third FT3 quartiles subpopulation, in which there were no relevant differences between patients with (n = 81) or without GO (n = 67) for baseline parameters. Within this population, the prevalence of IgG4 levels ≥ 135 mg/dL did not differ between patients without and with GO (17.9% vs 17.3%). No difference was observed concerning IgG4 concentrations, prevalence of IgG4/IgG ≥ 8.0%, and IgG4/IgG ratio. There was no relationship between IgG4 and eye features and no correlation between IgG4 levels and TRAb was found.
Conclusions
Our results suggest that, within GD, there is no relationship between serum IgG4 and GO.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366:539–551. https://doi.org/10.1056/NEJMra1104650
Sato Y, Notohara K, Kojima M (2010) IgG4-related disease: historical overview and pathology of hematological disorders. Pathol Int 60(4):247–258. https://doi.org/10.1111/j.1440-1827.2010.02524.x
Kamisawa T, Funata N, Hayashi Y (2003) A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 38(10):982–984. https://doi.org/10.1007/s00535-003-1175-y
Stone JH, Khosroshahi A, Hilgenberg A et al (2009) IgG4-related systemic disease and lymphoplasmacytic aortitis. Arthritis Rheum 60(10):3139–3145. https://doi.org/10.1002/art.24798
Saeki T, Saito A, Hiura T et al (2006) Lymphoplasmacytic infiltration of multiple organs with immunoreactivity for IgG4: IgG4-related systemic disease. Intern Med 45(3):163–167. https://doi.org/10.2169/internalmedicine.45.1431
Kamisawa T, Takuma K, Egawa N et al (2010) Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol 7(7):401–409. https://doi.org/10.1038/nrgastro.2010.81
Rotondi M, Carbone A, Coperchini F et al (2019) Diagnosis of endocrine disease: IgG4-related thyroid autoimmune disease. Eur J Endocrinol 180(5):R175–R183. https://doi.org/10.1530/EJE-18-1024
Zhang J, Zhao L, Gao Y et al (2014) A classification of Hashimoto’s thyroiditis based on immunohistochemistry for IgG4 and IgG. Thyroid 24(2):364–370. https://doi.org/10.1089/thy.2013.0211
Li Y, Bai Y, Liu Z et al (2009) Immunohistochemistry of IgG4 can help subclassify Hashimoto’s autoimmune thyroiditis. Pathol Int 59(9):636–641. https://doi.org/10.1111/j.1440-1827.2009.02419.x
Li Y, Nishihara E, Hirokawa M et al (2010) Distinct clinical, serological, and sonographic characteristics of Hashimoto’s thyroiditis based with and without IgG4-positive plasma cells. J Clin Endocrinol Metab 95(3):1309–1317. https://doi.org/10.1210/jc.2009-1794
Li Y, Zhou G, Ozaki T et al (2012) Distinct histopathological features of Hashimoto’s thyroiditis with respect to IgG4-related disease. Mod Pathol 25(8):1086–1097. https://doi.org/10.1038/modpathol.2012.68
Stan MN, Sonawane V, Sebo TJ et al (2017) Riedel’s thyroiditis association with IgG4-related disease. Clin Endocrinol (Oxf) 86(3):425–430. https://doi.org/10.1111/cen.13238
Dahlgren M, Khosroshahi A, Nielsen GP et al (2010) Riedel’s thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 62(9):1312–1318. https://doi.org/10.1002/acr.20215
Takeshima K, Inaba H, Furukawa Y et al (2014) Elevated serum immunoglobulin G4 levels in patients with Graves’ disease and their clinical implications. Thyroid 24(4):736–743. https://doi.org/10.1089/thy.2013.0448
Martin CS, Sirbu AE, Betivoiu MA et al (2017) Serum immunoglobulin G4 levels and Graves’ disease phenotype. Endocrine 55(2):478–484. https://doi.org/10.1007/s12020-016-1157-5
Torimoto K, Okada Y, Kurozumi A et al (2017) Clinical features of patients with Basedow’s disease and high serum IgG4 levels. Intern Med 56(9):1009–1013. https://doi.org/10.2169/internalmedicine.56.7824
Deng Y, Wang J, Zou G et al (2022) The characteristics and clinical significance of elevated serum IgG4/IgG levels in patients with Graves’ disease. Endocrine 75(3):829–836. https://doi.org/10.1007/s12020-021-02935-3
Ye H, Xiao W, Chen R et al (2020) Elevated immunoglobulin G4 levels in patients with thyroid eye disease and their clinical implications. Invest Ophthalmol Vis Sci 61(5):57. https://doi.org/10.1167/iovs.61.5.57
Bozkirli E, Bakiner OS, Ersozlu Bozkirli ED et al (2015) Serum immunoglobulin G4 levels are elevated in patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 83(6):962–967. https://doi.org/10.1111/cen.12671
Luo B, Yuan X, Wang W et al (2022) Ocular Manifestations and Clinical Implications of Serum Immunoglobulin G4 Levels in Graves’ Ophthalmopathy Patients. Ocul Immunol Inflamm 30(3):580–587. https://doi.org/10.1080/09273948.2020.1826537
Yu SH, Kang JG, Kim CS et al (2017) Clinical Implications of Immunoglobulin G4 to Graves’ Ophthalmopathy. Thyroid 27(9):1185–1193. https://doi.org/10.1089/thy.2017.0126
Olejarz M, Szczepanek-Parulska E, Ostalowska-Klockiewicz, A et al (2023) High IgG4 serum concentration is associated with active Graves’ orbitopathy. Front Endocrinol 14:1083321. https://doi.org/10.3389/fendo.2023.1083321
Umehara H, Okazaki K, Kawa S et al (2021) The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31(3):529–533. https://doi.org/10.1080/14397595.2020.1859710
Masaki Y, Kurose N, Yamamoto M et al (2012) Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related disease. Int J Rheumatol 2012:580814. https://doi.org/10.1155/2012/580814
Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves’ orbitopathy. Eur J Endocrinol 185:G43–G67
Olejarz M, Szczepanek-Parulska E, Dadej D et al (2021) IgG4 as a biomarker in Graves’ orbitopathy. Mediators Inflammat 2021:5590471. https://doi.org/10.1155/2021/5590471
Sarić Matutinović M, Kahaly GJ, Žarković M et al (2023) The phenotype of Graves’ orbitopathy is associated with thyrotropin receptor antibody levels. J Endocrinol Invest. https://doi.org/10.1007/s40618-023-02085-5
Eckstein A, Esser J, Mann K et al (2010) Clinical value of TSH receptor antibodies measurement in patients with Graves’ orbitopathy. Pediatr Endocrinol Rev 7(Suppl 2):198–203
Nicolì F, Lanzolla G, Mantuano M et al (2021) Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy. J Endocrinol Invest 44(3):581–585. https://doi.org/10.1007/s40618-020-01353-y
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest. Michele Marinò is a member of the Journal of Endocrinological Investigation Editorial Board.
Informed consent
Informed consent was obtained from the individual participant included in the study.
Ethical approval
The study was performed according to Institutional guidelines. Approval was not required. All procedure performed in the study involving human participants were in accordance with the ethical standards of th
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Comi, S., Lanzolla, G., Cosentino, G. et al. IgG4 serum levels in Graves’ orbitopathy. J Endocrinol Invest (2023). https://doi.org/10.1007/s40618-023-02265-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40618-023-02265-3